Tocilizumab for the treatment of juvenile idiopathic arthritis;Le tocilizumab pour le traitement de l'arthrite juvénile idiopathique

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages 822-829

  Decelle, Kendra ^a   Horton, Evan R ^b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Anti interleukin 6; Juvenile idiopathic arthritis; Tocilizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE ACTIVATION; BACTERIAL ARTHRITIS; BINDING COMPETITION; BRONCHITIS; CHICKENPOX; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HERPES ZOSTER; HUMAN; INFECTIOUS MONONUCLEOSIS; INSECT BITE; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE; MOUTH ULCER; NEUTROPENIA; PANCYTOPENIA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUSTULE; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE RHEUMATOID; DRUG LABELING; HUMANS; INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 84862267344     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q756     Document Type: Article

References (25)

1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis. 2nd revision. Edmonton, 2001. J Rheumatol 2004;31:390-2.
2. Herlin T. Tocilizumab: the evidence for its place in the treatment of juvenile idiopathic arthritis. Core Evid 2009;4:181-9.
3. Kahn P. Juvenile idiopathic arthritis: an update on pharmacology. Bull NYC Hosp Jt Dis 2011;69:264-76.
4. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
5. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:386-91.
6. US Food and Drug Administration, April 2011. FDA approves Actemra to treat rare form of juvenile arthritis (press release). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251572.htm. (accessed 2011 Sept 19).
7. Hoffmann-La Roche. A randomized, placebo-controlled study to evaluate the effect of tocilizumab on disease response in patients with active systemic juvenile idiopathic arthritis (JIA), with an open-label extension to examine the long term use of tocilizumab (TENDER trial). Bethesda, MD: National Library of Medicine, 2000-2011, (NLM identifier: NCT00642460). www.clinicaltrials.gov/show/NCT00642460 (accessed 2011 Sept 19).
8. Gold Standard, Inc. Tocilizumab. Clinical Pharmacology (database online). www.clinicalpharmacology.com (accessed 2011 Nov 2).
9. Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 2011;585:3699-709.
10. Yokota Y. Interleukin 6 as a target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003;15:581-6.
11. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7.
12. Tocilizumab. Clinicaltrials.gov. www.clinicaltrials.gov (accessed 2011 Aug 30).
13. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009;21:221-30.
14. Choy E. Clinical experience with inhibition of interleukin-6. Rheum Dis Clin North Am 2004;30:405-15.
15. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
16. Zhang X, Morcos PN, De Benedetti F, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA) (abstract FRI0200). Ann Rheum Dis 2011;70.
17. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 2010;50:754-66.
18. Keizer RJ, Huitema A, Schellend J, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493-507.
19. Package insert. Actemra (tocilizumab). Basel, Switzerland: F. Hoffman-La Roche Ltd, September 2008.
20. Woo P, Wilkinson N, Prieur A, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7:R1281-8.
21. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52: 818-25.
22. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
23. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6- receptor monoclonal antibody, in patients with polyarticular- course juvenile idiopathic arthritis. Mod Rheumatol Epub 12 Jun 2011. (In press).
24. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
25. Yokota Y, Imagawa T, Takei S, et al. Guidance on using tocilizumab for juvenile idiopathic arthritis. Mod Rheumatol 2011;21:563-71.